Literature DB >> 17335188

Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist.

Jean Rivier1, Jozsef Gulyas, Koichi Kunitake, Michael DiGruccio, Jeffrey P Cantle, Marilyn H Perrin, Cindy Donaldson, Joan Vaughan, Mulugeta Million, Guillaume Gourcerol, David W Adelson, Catherine Rivier, Yvette Taché, Wylie Vale.   

Abstract

The potencies and selectivity of peptide CRF antagonists is increased through structural constraints, suggesting that the resulting ligands assume distinct conformations when interacting with CRF1 and CRF2 receptors. To develop selective CRF receptor agonists, we have scanned the sequence -Gln-Ala-His-Ser-Asn-Arg- (residues 30-35 of [DPhe12,Nle21,38]Ac-hCRF4-41) with an i-(i+3) bridge consisting of the Glui-Xaa-Xbb-Lysi+3 scaffold, where residues i=30, 31, and 32. When i=31, stressin1-A, a potent CRF1 receptor-selective agonist was generated. In vitro, stressin1-A was equipotent to h/rCRF to release ACTH. Astressin1-A showed a low nanomolar affinity for CRF1 receptor (Ki=1.7 nM) and greater than 100-fold selectivity versus CRF2 receptor (Ki=222 nM). Stressin1-A released slightly less ACTH than oCRF in adult adrenal-intact male rats, with increased duration of action. Stressin1-A, injected intraperitoneally in rats, induced fecal pellet output (a CRF1 receptor-mediated response) and did not influence gastric emptying and blood pressure (CRF2 receptor-mediated responses).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335188      PMCID: PMC2593142          DOI: 10.1021/jm0613875

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

Review 1.  International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands.

Authors:  Richard L Hauger; Dimitri E Grigoriadis; Mary F Dallman; Paul M Plotsky; Wylie W Vale; Frank M Dautzenberg
Journal:  Pharmacol Rev       Date:  2003-03       Impact factor: 25.468

2.  Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2.

Authors:  L Wang; V Martínez; J E Rivier; Y Taché
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-11       Impact factor: 3.619

3.  Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats.

Authors:  Mulugeta Million; Céline Maillot; Paul Saunders; Jean Rivier; Wylie Vale; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-01       Impact factor: 4.052

4.  Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.

Authors:  S C Coste; R A Kesterson; K A Heldwein; S L Stevens; A D Heard; J H Hollis; S E Murray; J K Hill; G A Pantely; A R Hohimer; D C Hatton; T J Phillips; D A Finn; M J Low; M B Rittenberg; P Stenzel; M P Stenzel-Poore
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

5.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

6.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2.

Authors:  Vicente Martínez; Lixin Wang; Jean E Rivier; Wylie Vale; Yvette Taché
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats.

Authors:  M Million; L Wang; Y Wang; D W Adelson; P-Q Yuan; C Maillot; S V Coutinho; J A Mcroberts; A Bayati; H Mattsson; V Wu; J-Y Wei; J Rivier; W Vale; E A Mayer; Y Taché
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

9.  Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.

Authors:  J Rivier; J Gulyas; D Kirby; W Low; M H Perrin; K Kunitake; M DiGruccio; J Vaughan; J C Reubi; B Waser; S C Koerber; V Martinez; L Wang; Y Taché; W Vale
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

Review 10.  Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress.

Authors:  Sarah C Coste; Robert F Quintos; Mary P Stenzel-Poore
Journal:  Trends Cardiovasc Med       Date:  2002-05       Impact factor: 6.677

View more
  26 in total

1.  Activation of neuropeptide S-expressing neurons in the locus coeruleus by corticotropin-releasing factor.

Authors:  Kay Jüngling; Xiaobin Liu; Jörg Lesting; Philippe Coulon; L Sosulina; Rainer K Reinscheid; Hans-Christian Pape
Journal:  J Physiol       Date:  2012-05-08       Impact factor: 5.182

2.  Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Sandra Braun; Judith Hernandez-Aranda; Christine C Hudson; Eric Gutknecht; Frank M Dautzenberg; Robert H Oakley
Journal:  Regul Pept       Date:  2013-06-29

3.  VIP is involved in peripheral CRF-induced stimulation of propulsive colonic motor function and diarrhea in male rats.

Authors:  Seiichi Yakabi; Lixin Wang; Hiroshi Karasawa; Pu-Qing Yuan; Kazuhiko Koike; Koji Yakabi; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

4.  Activation of Type 1 CRH receptor isoforms induces serotonin release from human carcinoid BON-1N cells: an enterochromaffin cell model.

Authors:  S Vincent Wu; Pu-Qing Yuan; Jim Lai; Kelvin Wong; Monica C Chen; Gordon V Ohning; Yvette Taché
Journal:  Endocrinology       Date:  2010-12-01       Impact factor: 4.736

Review 5.  Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.

Authors:  Yvette Tache; Muriel Larauche; Pu-Qing Yuan; Mulugeta Million
Journal:  Curr Mol Pharmacol       Date:  2018       Impact factor: 3.339

Review 6.  Synaptic physiology of central CRH system.

Authors:  Joel P Gallagher; Luis F Orozco-Cabal; Jie Liu; Patricia Shinnick-Gallagher
Journal:  Eur J Pharmacol       Date:  2008-02-01       Impact factor: 4.432

7.  Corticotropin releasing factor and catecholamines enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala.

Authors:  Yuval Silberman; Danny G Winder
Journal:  Neuropharmacology       Date:  2013-03-05       Impact factor: 5.250

8.  Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats.

Authors:  P-Q Yuan; M Million; S V Wu; J Rivier; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2007-08-10       Impact factor: 3.598

9.  Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.

Authors:  Muriel Larauche; Guillaume Gourcerol; Lixin Wang; Karina Pambukchian; Stefan Brunnhuber; David W Adelson; Jean Rivier; Mulugeta Million; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-30       Impact factor: 4.052

10.  CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior.

Authors:  Michael R Bruchas; Benjamin B Land; Julia C Lemos; Charles Chavkin
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.